Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2013. The report details a specific share repurchase transaction executed on September 17, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,240,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,625 pence per share; lowest price paid was 1,611.50 pence per share.
- Treasury Holdings (Settled): 520,172,412 shares, representing 9.61% of total issued share capital.
- Treasury Holdings (Including Unsettled): 523,879,412 shares, representing 10.70% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,894,470,925 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,240,000 shares on September 17, 2013. This transaction increased the company's treasury share holdings to over 10% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (520,172,412 settled) against the company's latest capitalization table.
- Confirm the percentage of voting rights held in Treasury (10.70% including unsettled) for disclosure threshold calculations.
- Check the remaining authorized share buyback limit following this transaction.
- Review the settlement status of the 3,706,999 shares included in the "unsettled" count to determine final treasury holdings.